BluumBio
Developing microbial and plant-based bioremediation products to break down industrial contaminants.
Website: https://www.bluumbio.com/
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Name | BluumBio |
| Tagline | Developing microbial and plant-based bioremediation products to break down industrial contaminants [bluumbio.com] |
| Headquarters | Berkeley, United States [ycombinator.com] |
| Founded | 2021 [ycombinator.com] |
| Stage | Seed [healthcarediscovery.ai, Oct 2024] |
| Business model | B2B [ycombinator.com, Unknown] |
| Industry | Cleantech / Climatetech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Solo Founder, Katherine French [eqtgroup.com] |
| Funding label | Undisclosed [plugandplaytechcenter.com, Jan 2026] |
Links
Publicly reported
- Website: https://www.bluumbio.com/
- LinkedIn: https://www.linkedin.com/company/bluumbio
Summary and Signal
PUBLIC BluumBio develops microbial and plant-based bioremediation products for industrial contaminants, and it merits investor attention now because public signals suggest it is moving from research-led product development toward field validation and commercial deployment across regulated cleanup markets [bluumbio.com, Unknown] [EQT Group, May 2025] [Y Combinator, Unknown]. The company was founded in Berkeley in 2021 by Katherine French, who says the underlying work began at UC Berkeley; public profiles describe her as an environmental scientist and biologist with a DPhil in Plant Sciences from Oxford, which is relevant for a biology-first remediation platform but does not by itself establish scaled commercial execution history [bluumbio.com, Unknown] [EQT Group] [workatastartup.com, Unknown].
The product story is broader than a single point solution: BluumBio describes capabilities spanning organism discovery, enzyme optimization, and product development, with publicly referenced offerings for petroleum hydrocarbons, PFAS, PCBs, and plastics, plus treatability studies, field trials, and deployment support for industrial customers [LinkedIn] [EQT Group, May 2025] [Y Combinator, Unknown]. That framing matters because differentiation in remediation tends to rest less on software-style distribution and more on whether a company can pair biology with measurable site-level performance; BluumBio says its products have been used on real soil and water from customer sites, though named customers and outcome data are not disclosed in the sources reviewed [watertoday.ca] [bluumbio.com, Unknown].
On financing, the public record points to an undisclosed pre-seed in 2021, YC participation, inclusion in the Founders Factory and Rio Tinto-backed Mining Tech Accelerator in October 2024, EQT Foundation participation in a May 2025 seed round, and a $188,466 NIH-related grant listing in July 2025 [Plug and Play Tech Center, Jan 2026] [Y Combinator, Unknown] [healthcarediscovery.ai, Oct 2024] [EQT Group, May 2025] [healthcareventurecapitalfund.com, Jul 2025]. The business model appears B2B and services-assisted, selling bio-based remediation products alongside testing and deployment work, which can help early adoption in cautious industrial accounts but may also slow pure product scaling if each engagement remains technically bespoke [Y Combinator, Unknown] [watertoday.ca].
Over the next 12 to 18 months, the public markers to watch are straightforward: whether PFAS and other field trials convert into named commercial relationships, whether the company expands beyond a very small team footprint, and whether investor-backed pilots translate into repeatable demand rather than one-off scientific validation [EQT Group, May 2025] [getlatka.com] [RocketReach]. The setup is interesting because BluumBio sits at the intersection of climate, industrial biotech, and environmental compliance, but the investability question still turns on independent proof of deployment outcomes, customer concentration, and the degree to which remediation efficacy holds across contaminants and sites [bluumbio.com, Unknown] [EQT Group, May 2025].
No independent source found -- This section relies materially on company, investor, and platform profiles, with limited independent public corroboration for product efficacy, customer adoption, and operating metrics.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Cleantech / Climatetech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Undisclosed |
Company Overview
PUBLIC BluumBio traces back to Berkeley in 2021, where founder Katherine French says she developed the underlying work before forming the company [bluumbio.com]. Public company materials describe BluumBio as a biotechnology business developing microbial and plant-based bioremediation products for industrial contaminants, with headquarters listed in Berkeley, California [bluumbio.com] [Crunchbase].
The public chronology is still thin, but a few milestones are visible. The company appears in Y Combinator's Summer 2021 cohort according to its YC profile, and Crunchbase records BluumBio as founded in 2021 [Crunchbase]. BluumBio's own site now presents a broader remediation scope across soil, water, air, and manufacturing waste streams, which suggests the company has moved from a research-origin story toward a commercialization posture, though the timing of that shift is not pinned down in state filings or Crunchbase entries reviewed here [bluumbio.com] [Crunchbase].
A legal entity name and incorporation record are not established in the cited public materials used for this section. That leaves some ordinary diligence questions, including exact formation date and entity structure, to primary documents rather than marketing or investor pages [Crunchbase] [bluumbio.com].
One source, partially checked -- Confirmed in part by Crunchbase and the company website; legal entity details are not established in the public sources used for this section.
The Product and the Stack
The Product and the Stack
MIXED BluumBio is selling a bioremediation workflow rather than a single point product, at least in the public record. The company describes microbial and plant-based products designed to break down industrial contaminants in soil, water, air, and manufacturing waste streams [bluumbio.com] [datanyze.com, Retrieved 2026]. Across its public profiles, the platform is framed as covering organism discovery, enzyme optimization, and product development, with services around treatability studies, field trials, and deployment support for industrial customers [LinkedIn] [Y Combinator].
The named product set is broader than many seed-stage climate biotech companies disclose publicly, but the evidence is still mostly company-originated. Bluum Helios is described as a shelf-stable microbial blend for petroleum hydrocarbon degradation, Bluum Delta as a PFAS remediation product, Bluum Firefly as a PCB remediation product, and Bluum Maris as a plastics-focused microbial treatment with use cases in composting and water systems [bluumbio.com] [EQT Group, May 2025]. EQT Foundation also said in May 2025 that BluumBio was working on petroleum-product treatment, a PFAS solution, and products targeting PCBs and plastics, which provides some outside corroboration on category focus, though not on performance claims [EQT Group, May 2025].
The clearest sign of technical activity beyond website copy is that BluumBio says its products have been used on real soil and water from customer sites, and its August 2026 Sydney microbiologist role references water and soil treatability studies with Australian partners [Water Today] [Y Combinator, Aug 2026]. That supports a view that the company is operating at least part of the stack as applied field remediation, not only lab R&D. What remains unverified in public sources is comparative efficacy, remediation speed, regulatory acceptance, and whether the same organism-enzyme platform generalizes cleanly across hydrocarbons, PFAS, PCBs, and plastics.
No independent source found -- Product descriptions rely heavily on company-owned sources, with limited outside corroboration from EQT Group, Water Today, and a Y Combinator job posting.
The Market They Are Entering
PUBLIC The market matters now because industrial contaminant cleanup is shifting from a compliance cost toward a technology procurement category, especially where PFAS, petroleum residues, and legacy chemicals are forcing site owners to test alternatives to excavation, incineration, and chemical treatment [EQT Group, May 2025] [Water Today] [Y Combinator].
Public sources on BluumBio do not provide a directly cited TAM, SAM, or SOM from a named third-party market report, so the cleaner read is to frame demand through the contaminant classes and customer segments the company itself and its investors are targeting. Those segments include oil and gas, mining, wastewater, aerospace, airports, chemicals, and engineering firms, with a delivery model that appears to pair biological products with treatability studies, field trials, and deployment support rather than only selling a packaged input [bluumbio.com] [Y Combinator] [Work at a Startup] [EQT Group, May 2025]. That matters for market definition: BluumBio is not only selling into bioremediation inputs, it is also touching the environmental services budget that sits around testing, pilot work, and site-specific deployment [Y Combinator] [Water Today].
Demand drivers in the public record are specific even if revenue visibility is thin. EQT Foundation said its May 2025 investment would support commercialization, PFAS field trials, and further development of PCB and plastics products, which signals that buyer interest is at least strong enough to justify field validation work across multiple pollutant classes [EQT Group, May 2025]. The Sydney microbiologist role posted through Y Combinator in August 2026 adds another practical signal: BluumBio said the role would support water and soil treatability studies with Australian partners, suggesting that customer evaluation is happening close to contaminated sites and outside the Bay Area lab environment [Y Combinator, Aug 2026].
The adjacent markets are broader than remediation chemistry alone. BluumBio's public materials place it at the intersection of environmental testing, industrial wastewater treatment, hazardous site remediation, and, in some use cases, waste and materials management for plastics degradation [bluumbio.com] [EQT Group, May 2025]. Substitute approaches include excavation and disposal, thermal destruction, and other chemical or physical remediation methods, which is why the company's biological pitch has to win on field performance, handling, and project economics rather than novelty by itself [Water Today] [bluumbio.com].
Regulation is the clearest macro tailwind visible in the sources, though the evidence is indirect. A company that is publicly building products for PFAS, PCBs, petroleum hydrocarbons, and plastics is aligning itself with contaminant categories that already sit inside established industrial cleanup and water-treatment workflows, not with a newly invented budget line [EQT Group, May 2025] [bluumbio.com]. The NIH-linked grant recorded in July 2025, while modest at $188,466, also suggests that at least some of the underlying environmental-health problem set fits public funding priorities, even if the grant amount is not material enough on its own to define commercial demand [Healthcare Venture Capital Fund, Jul 2025].
| Market lens | Public evidence | Implication |
|---|---|---|
| Industrial remediation buyers | BluumBio names oil and gas, mining, wastewater, airports, aerospace, chemicals, and engineering firms as target customers [bluumbio.com] [Work at a Startup] | Demand is likely budgeted within existing environmental remediation and industrial services spend rather than a new software category. |
| Contaminant classes | Public product work includes petroleum treatment, PFAS, PCBs, and plastics [EQT Group, May 2025] [bluumbio.com] | The addressable opportunity spans several pollutant-specific workflows, but each may require separate proof and channel development. |
| Services attachment | BluumBio describes treatability studies, field trials, and deployment support alongside products [Y Combinator] | Early market entry may depend on consultative sales and project work, which can aid adoption but may limit speed of scale. |
| Geographic expansion signal | August 2026 job posting references Australian partners and a Sydney lab workflow [Y Combinator, Aug 2026] | Demand may travel to regions with active mining and water-treatment needs, though this is still an expansion signal rather than proof of broad international traction. |
The table points to a market that is easier to validate qualitatively than size precisely from public data. The main attraction is that BluumBio appears to sit inside existing remediation budgets across several contaminant classes, but the open question is whether one platform can convert that breadth into repeatable procurement.
No independent source found -- This section relies mainly on company, investor, and program materials, with limited independent corroboration from Water Today and a job posting on Y Combinator.
The Competitive Field
MIXED BluumBio is positioned against a broad set of remediation alternatives rather than a clearly disclosed startup peer set, which means the practical competition is incumbent cleanup methods and industrial decision inertia as much as any one venture-backed company [bluumbio.com, Unknown] [ycombinator.com] [watertoday.ca].
The public record points first to category competition, not brand-against-brand rivalry. BluumBio describes microbial and plant-based products for petroleum hydrocarbons, PFAS, PCBs, and plastics, sold alongside treatability studies, field trials, and deployment support for industrial customers [eqtgroup.com, May 2025] [ycombinator.com]. In that frame, the incumbent map is fairly plain: contaminated-site owners can continue to use excavation, disposal, incineration, chemical treatment, or conventional engineering-led remediation programs instead of adopting a biological approach, while adjacent substitutes include consultants and remediation contractors that package diagnosis, permitting, and project management without owning the underlying biology [watertoday.ca] [workatastartup.com]. The absence of named public startup rivals in the sourced material is itself informative. It suggests BluumBio is still being described through use cases and contaminant classes, not through a stable head-to-head vendor set that outsiders can verify [eqtgroup.com, May 2025] [linkedin.com].
BluumBio's edge, to the extent it is visible publicly, appears to sit in technical breadth and founder-market fit rather than in an already-demonstrated distribution machine. The company presents a platform spanning organism discovery, enzyme optimization, and product development, and founder Katherine French is described as an environmental scientist and biologist with Oxford training and underlying work conducted at UC Berkeley [linkedin.com] [eqtgroup.com]. That combination can matter in bioremediation, where performance claims often depend on contaminant-specific biology rather than software iteration. Still, the durability of that edge looks mixed from public evidence. Scientific talent and proprietary formulations can be durable if they translate into repeatable field performance, but the current proof points are mostly company or investor descriptions, and the company is still small by public headcount signals, with sources citing four employees in 2024 and six employees in a later directory snapshot [getlatka.com] [rocketreach.co, Retrieved 2026]. A small technical team can move quickly, but it also makes institutional depth and parallel deployment capacity perishable advantages if larger environmental services firms decide to replicate or partner around similar methods.
The clearest exposure is commercial, not conceptual. BluumBio cites customers across oil and gas, mining, wastewater, airports, aerospace, chemicals, and engineering, but the reviewed public sources do not name reference accounts, contract scale, or repeat deployment volume [watertoday.ca] [workatastartup.com]. That leaves the company vulnerable to incumbents that already control site access, procurement relationships, and compliance workflows, even if their underlying remediation methods are less biologically novel. There is also product-scope risk inside the contaminant mix. PFAS and PCB remediation carry high evidentiary and regulatory scrutiny, so any competitor or substitute with stronger validation, permitting experience, or balance-sheet capacity could hold an advantage in enterprise or government procurement cycles [eqtgroup.com, May 2025]. BluumBio's open role in Sydney and its participation in the Founders Factory and Rio Tinto-backed Mining Tech Accelerator indicate growing geographic and mining-sector relevance, but they do not yet establish a proprietary channel that others cannot access [ycombinator.com, Aug 2026] [healthcarediscovery.ai, Oct 2024].
Over the next 18 months, the most plausible competitive scenario is that procurement credibility matters more than scientific novelty alone. Winner if industrial pilots convert into named repeat deployments: Rio Tinto, as a program backer and potential first customer through the Mining Tech Accelerator, could become the most consequential ecosystem winner because a large industrial reference would validate BluumBio's approach and create a distribution signal beyond the lab [healthcarediscovery.ai, Oct 2024]. Loser if field results fail to generalize across sites: BluumBio itself, because a services-plus-product model with undisclosed customer logos and limited public operating scale leaves little room for category disappointment before buyers revert to established remediation programs [ycombinator.com] [watertoday.ca]. The upside case is real, particularly where petroleum hydrocarbons or mining-linked contamination offer faster proof cycles than the hardest PFAS claims, but the competitive balance still turns on validation in the field, not on narrative positioning [eqtgroup.com, May 2025] [bluumbio.com, Unknown].
com, Unknown] [eqtgroup.com, May 2025] [healthcarediscovery.ai, Oct 2024].
Opportunity
Upside case
PUBLIC The prize here is not a niche remediation supplier but a new biological remediation platform that could sit inside industrial cleanup workflows across petroleum hydrocarbons, PFAS, PCBs, and plastics, if BluumBio can turn early product breadth and field validation into repeatable enterprise adoption [bluumbio.com, Unknown] [EQT Group, May 2025] [watertoday.ca].
The most credible headline opportunity is that BluumBio becomes a category-shaping specialist in biologically based contaminant treatment, selling both products and the applied services needed to get those products approved and deployed at industrial sites [Y Combinator] [LinkedIn]. That outcome is reachable, not merely aspirational, because the public record shows three ingredients already in place: a founder with domain training in plant sciences and environmental biology [EQT Group] [bluumbio.com, Unknown], a product set aimed at several contaminant classes rather than a single point solution [EQT Group, May 2025] [bluumbio.com, Unknown], and investor or program access to industrial ecosystems that matter in remediation, including Y Combinator, Plug and Play, the Mining Tech Accelerator, Rio Tinto, and EQT Foundation [Y Combinator] [Plug and Play Tech Center, Jan 2026] [healthcarediscovery.ai, Oct 2024] [EQT Group, May 2025]. In plain terms, the company is trying to own the biological layer of cleanup work that incumbents often address with excavation, chemical treatment, or thermal methods, and the existence of treatability studies, field trials, and deployment support in its commercial model suggests management understands that adoption in this market is won in the field, not only in the lab [Y Combinator] [watertoday.ca].
A plausible path to scale is easier to see when broken into a few distinct routes. The table below is not a forecast. It maps public evidence to the most credible upside scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Industrial wedge, multi-contaminant expansion | BluumBio wins initial deployments in one contaminant class, then expands the same customer into adjacent contaminants and sites | A successful PFAS or petroleum field trial that converts into broader enterprise remediation work [EQT Group, May 2025] [bluumbio.com, Unknown] | The company already publicly describes products for petroleum hydrocarbons, PFAS, PCBs, and plastics, which supports cross-sell logic if one use case proves itself first [EQT Group, May 2025] [bluumbio.com, Unknown] |
| Mining and heavy industry channel | BluumBio uses accelerator and investor relationships to secure reference deployments with mining and industrial partners | The Founders Factory and Rio Tinto Mining Tech Accelerator, which offered seed capital, support, and the possibility of Rio Tinto as a first customer [healthcarediscovery.ai, Oct 2024] | Mining produces persistent contamination and site-specific cleanup needs, and BluumBio has already been selected into a program designed around that buyer set [healthcarediscovery.ai, Oct 2024] |
| Australia-led field commercialization | BluumBio converts treatability work in Australia into a repeatable regional go-to-market motion for soil and water remediation | Ongoing water and soil treatability studies with Australian partners from a Sydney lab footprint [Y Combinator, Aug 2026] | The open microbiologist role points to active partner work in Australia, which is a stronger signal than a generic hiring plan because it ties staffing to current studies and field activity [Y Combinator, Aug 2026] |
The compounding logic is straightforward if the first few deployments work. Each site study can generate more contaminant-specific performance data, application know-how, and formulation refinements, which should improve the next sales cycle and reduce customer hesitation for similar sites [Y Combinator] [LinkedIn]. BluumBio's model already pairs products with treatability studies, field trials, and deployment support, so the service layer is not a distraction from the product. It may be the mechanism by which product credibility is built account by account [Y Combinator] [watertoday.ca]. The early signs of that flywheel are modest but visible in public sources: the company says it has treated real soil and water from customer sites, is running partner work in Australia, and has attracted backers that can introduce industrial counterparties rather than only provide capital [watertoday.ca] [Y Combinator, Aug 2026] [EQT Group, May 2025].
The size of the win is hard to anchor precisely because the source set does not include a confirmed market-sizing study or clean public comparables for BluumBio's exact model. Even so, there is a reasonable scenario frame. If BluumBio became a trusted biological remediation platform with recurring product revenue plus services pull-through across multiple industrial verticals, the business could support venture-scale outcomes because environmental remediation spend is attached to regulated, non-discretionary problems rather than optional software budgets. Public evidence of a reported $5 million revenue run rate with a four-person team in 2024, if directionally accurate, suggests the company may already have shown unusual commercial efficiency for its stage [GetLatka]. A business compounding from that base into a diversified industrial remediation supplier could plausibly justify a substantial strategic or late-stage private valuation in the hundreds of millions of dollars, or more, if it proves repeatable field performance across several contaminant classes (scenario, not a forecast) [GetLatka] [EQT Group, May 2025] [healthcarediscovery.ai, Oct 2024]. That upside case depends less on a single scientific breakthrough than on whether BluumBio can make biological cleanup dependable enough to become standard practice inside large contaminated-site workflows.
No independent source found -- This section relies heavily on company, investor, accelerator, and profile-page sources; several core product and traction claims remain company-side or single-source, with limited independent public corroboration.
Sources
Publicly reported
[bluumbio.com] BluumBio | https://www.bluumbio.com/
[ycombinator.com] BLUUMBIO: We make bacteria and plants that clean up pollution. | Y Combinator | https://www.ycombinator.com/companies/bluumbio
[healthcarediscovery.ai, Oct 2024] BluumBio | https://healthcarediscovery.ai/companies/bluumbio/
[plugandplaytechcenter.com, Jan 2026] New Investment: BluumBio, leveraging bioremediation to degrade cross-industry contaminants | https://www.plugandplaytechcenter.com/announcing-our-investment-in/new-investment-bluumbio-leveraging-bioremediation-to-degrade-cross-industry-contaminants/
[eqtgroup.com, May 2025] EQT Foundation invests in BluumBio, harnessing the power of nature to clean up pollution | https://eqtgroup.com/news/eqt-foundation-invests-in-bluumbio-harnessing-the-power-of-nature-to-clean-up-pollution
[workatastartup.com] BluumBio | https://www.workatastartup.com/companies/bluumbio
[linkedin.com] BLUUMBIO | LinkedIn | https://www.linkedin.com/company/bluumbio
[watertoday.ca] BluumBio | https://watertoday.ca/viewarticle.asp?article=580
[healthcareventurecapitalfund.com, Jul 2025] BluumBio | https://healthcareventurecapitalfund.com/companies/bluumbio/
[crunchbase.com] BluumBio - Recent News & Activity | https://www.crunchbase.com/organization/bluumbio/company_overview/overview_timeline
[datanyze.com, Retrieved 2026] BluumBio | https://www.datanyze.com/companies/bluumbio
[ycombinator.com, Aug 2026] Part-Time Microbiologist | Y Combinator | https://www.ycombinator.com/companies/bluumbio/jobs/B6IP20z-part-time-microbiologist
[rocketreach.co, Retrieved 2026] Jordan Baker email address & phone number | BLUUMBIO Chief Technology Officer contact information | https://rocketreach.co/jordan-baker-email_50387080
[eqtgroup.com] BluumBio - EQT Portfolio Company | https://eqtgroup.com/about/current-portfolio/bluumbio
[getlatka.com] How BLUUMBIO hit $5M revenue with a 4 person team in 2024 | https://getlatka.com/companies/bluumbio.com
Articles about BluumBio
- BluumBio's Microbial Cleanup Crew Takes On PFAS and Petroleum — The Berkeley biotech startup, backed by YC and EQT, is developing a suite of biological products to degrade everything from PFAS to plastics in soil and water.